President, Takeda's global oncology business unit
Appears in 1 story
Leading Mimrylo's commercial launch
Polycythemia vera has been treated with bloodletting for more than a century. On August 28, the FDA approved Mimrylo (rusfertide), the first drug that works instead by mimicking hepcidin, the hormone that limits iron available for new red blood cells.
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
